Ambalal Sarabhai Enterprises Limited (BOM:500009)
India · Delayed Price · Currency is INR | Market Cap | 2.92B +15.4% |
| Revenue (ttm) | 2.06B +4.5% |
| Net Income | 135.56M +5.8% |
| EPS | 1.77 +8.6% |
| Shares Out | 76.63M |
| PE Ratio | 21.57 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,280 |
| Open | 37.60 |
| Previous Close | 38.15 |
| Day's Range | 36.85 - 38.69 |
| 52-Week Range | 23.12 - 49.98 |
| Beta | 0.01 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About BOM:500009
Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures and markets pharmaceutical, molecular diagnostics, and electronic products in India and internationally. The company is involved in the supply of pharmaceutical preparations, such as finished dosage forms and active pharmaceutical ingredients; manufacture of fermentation-based pharmaceutical products; and manufacturing and marketing analytical, laboratory, and test and measuring instruments. It also engages in the marketing and distributing professional broadcast... [Read more]
Financial Performance
In fiscal year 2026, BOM:500009's revenue was 2.03 billion, an increase of 2.64% compared to the previous year's 1.97 billion. Earnings were 178.04 million, an increase of 261.05%.
Financial StatementsNews
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
Co-Diagnostics Inc. (NASDAQ: CODX) on Friday signed an agreement for CoSara Diagnostics Pvt. Ltd , to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakista...